Emerging Role of the IL-36/IL-36R Axis in Multiple Inflammatory Skin Diseases
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
IL-36 is a most recent member of the IL-1 cytokine family, primarily expressed at barrier sites of the body such as the skin, lungs, and intestine. It plays a vital role in inflammation and is implicated in the development of various cutaneous; intestinal; and pulmonary disorders, including psoriasis, inflammatory bowel disease, and chronic obstructive pulmonary disease. IL-36 comprises 4 isoforms: the proinflammatory IL-36α, IL-36β, and IL-36γ and the anti-inflammatory IL-36R antagonist. An imbalance between proinflammatory and anti-inflammatory IL-36 isoforms can contribute to the inflammatory fate of cells and tissues. IL-36 cytokines signal through an IL-36R heterodimer mediating their function through canonical signaling cacade, including the NF-B pathway. Prominent for its role in psoriasis, IL-36 has recently been associated with disease mechanisms in atopic dermatitis, hidradenitis suppurativa, neutrophilic dermatoses, autoimmune blistering disease, and Netherton syndrome. The major cutaneous source of IL-36 cytokines is keratinocytes, pointing to its role in the communication between the epidermis, innate (neutrophils, dendritic cells) immune system, and adaptive (T helper [Th]1 cells, Th17) immune system. Thus, cutaneous IL-36 signaling is crucial for the immunopathological outcome of various skin diseases. Consequently, the IL-36/IL-36R axis has recently been recognized as a promising drug target for the treatment of inflammatory disorders beyond psoriasis. This review summarizes the current update on IL-36 cytokines in inflammatory skin diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:144 |
|---|---|
| Enthalten in: |
The Journal of investigative dermatology - 144(2024), 2 vom: 05. Feb., Seite 206-224 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ahmad, Fareed [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.02.2024 Date Revised 06.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jid.2023.11.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366803271 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366803271 | ||
| 003 | DE-627 | ||
| 005 | 20240206232108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jid.2023.11.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM366803271 | ||
| 035 | |a (NLM)38189700 | ||
| 035 | |a (PII)S0022-202X(23)03114-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ahmad, Fareed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging Role of the IL-36/IL-36R Axis in Multiple Inflammatory Skin Diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.02.2024 | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a IL-36 is a most recent member of the IL-1 cytokine family, primarily expressed at barrier sites of the body such as the skin, lungs, and intestine. It plays a vital role in inflammation and is implicated in the development of various cutaneous; intestinal; and pulmonary disorders, including psoriasis, inflammatory bowel disease, and chronic obstructive pulmonary disease. IL-36 comprises 4 isoforms: the proinflammatory IL-36α, IL-36β, and IL-36γ and the anti-inflammatory IL-36R antagonist. An imbalance between proinflammatory and anti-inflammatory IL-36 isoforms can contribute to the inflammatory fate of cells and tissues. IL-36 cytokines signal through an IL-36R heterodimer mediating their function through canonical signaling cacade, including the NF-B pathway. Prominent for its role in psoriasis, IL-36 has recently been associated with disease mechanisms in atopic dermatitis, hidradenitis suppurativa, neutrophilic dermatoses, autoimmune blistering disease, and Netherton syndrome. The major cutaneous source of IL-36 cytokines is keratinocytes, pointing to its role in the communication between the epidermis, innate (neutrophils, dendritic cells) immune system, and adaptive (T helper [Th]1 cells, Th17) immune system. Thus, cutaneous IL-36 signaling is crucial for the immunopathological outcome of various skin diseases. Consequently, the IL-36/IL-36R axis has recently been recognized as a promising drug target for the treatment of inflammatory disorders beyond psoriasis. This review summarizes the current update on IL-36 cytokines in inflammatory skin diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Atopic Dermatitis | |
| 650 | 4 | |a Interleukin-36 | |
| 650 | 4 | |a Keratinocytes | |
| 650 | 4 | |a Psoriasis | |
| 650 | 4 | |a Skin inflammation | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Interleukin-1 |2 NLM | |
| 650 | 7 | |a Protein Isoforms |2 NLM | |
| 650 | 7 | |a IL36A protein, human |2 NLM | |
| 650 | 7 | |a IL36B protein, human |2 NLM | |
| 650 | 7 | |a IL36RN protein, human |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin-1 |2 NLM | |
| 700 | 1 | |a Alam, Majid Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Ansari, Abdul Wahid |e verfasserin |4 aut | |
| 700 | 1 | |a Jochebeth, Anh |e verfasserin |4 aut | |
| 700 | 1 | |a Leo, Rari |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Abdulla, Mohammed Nasser |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Khawaga, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a AlHammadi, Ayda |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Malki, Aysha |e verfasserin |4 aut | |
| 700 | 1 | |a Al Naama, Khalifa |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Aamir |e verfasserin |4 aut | |
| 700 | 1 | |a Buddenkotte, Jörg |e verfasserin |4 aut | |
| 700 | 1 | |a Steinhoff, Martin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of investigative dermatology |d 1945 |g 144(2024), 2 vom: 05. Feb., Seite 206-224 |w (DE-627)NLM000018597 |x 1523-1747 |7 nnns |
| 773 | 1 | 8 | |g volume:144 |g year:2024 |g number:2 |g day:05 |g month:02 |g pages:206-224 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jid.2023.11.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 144 |j 2024 |e 2 |b 05 |c 02 |h 206-224 | ||